New study explores letrozole's effects on breast cancer before surgery

NCT ID NCT04568616

Ongoing Disease control Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug letrozole in postmenopausal women with early-stage ER+ breast cancer. Participants take letrozole for 4 to 24 weeks before surgery to see how the tumor changes and to check if they take the medication as prescribed. The goal is to improve treatment for this type of breast cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER ER POSITIVE BREAST CANCER

Contacts and locations

Locations

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States
Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.